ORG Wealth Partners LLC Purchases 4,279 Shares of Amgen Inc. (NASDAQ:AMGN)

ORG Wealth Partners LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 348.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,506 shares of the medical research company's stock after buying an additional 4,279 shares during the quarter. ORG Wealth Partners LLC's holdings in Amgen were worth $1,696,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $25,000. Pinney & Scofield Inc. bought a new stake in Amgen during the 4th quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE grew its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC purchased a new position in shares of Amgen during the 4th quarter valued at $34,000. Finally, Atala Financial Inc purchased a new position in shares of Amgen during the 4th quarter valued at $34,000. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on AMGN shares. Royal Bank Of Canada cut their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Piper Sandler lowered their price objective on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Cantor Fitzgerald assumed coverage on shares of Amgen in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price target for the company. Finally, UBS Group reissued a "neutral" rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $309.22.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.76% of the company's stock.

Amgen Stock Performance

AMGN stock traded down $0.30 on Friday, hitting $289.33. The company had a trading volume of 6,801,322 shares, compared to its average volume of 2,835,249. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The stock's 50-day simple moving average is $281.82 and its 200 day simple moving average is $285.96. The stock has a market cap of $155.58 billion, a price-to-earnings ratio of 26.40, a P/E/G ratio of 2.62 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same quarter last year, the company posted $3.96 earnings per share. The firm's quarterly revenue was up 9.4% on a year-over-year basis. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.